{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:58:41Z","timestamp":1781636321947,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100031949","name":"Guardant Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100031949","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Low-dose computed tomography (LDCT) remains the only validated modality for lung cancer screening, yet participation is suboptimal. Blood-based assays could eventually complement LDCT, but their performance for detecting early-stage disease in screening populations is uncertain. This study evaluated how well a cell-free DNA blood-based screening test can detect early-stage lung cancer in patients with LDCT screen-detected or incidental lung nodules.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We recruited patients via email with upcoming LDCT appointments whose results were classified under the Lung-RADS categories of 1\u20134. Guardant Health LUNAR\n                      <jats:sup>\u00ae<\/jats:sup>\n                      test collection kits were mailed to the participant. Participants provided a blood sample on the day of their LDCT visit, or within 30 days of the scan. Sensitivity and specificity were computed using the tumor registry as the gold standard and compared to assay results from the blood draw date closest to the date of diagnosis of cancer, but prior to receipt of any treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 765 participants, 18 lung cancers were diagnosed. Most of the study population had a previous lung cancer screen. Eleven cases were diagnosed with stage 1 disease (68.8%). The sensitivity was 43.8% (95% CI:19.4\u201368.1%) and the specificity was 84.1% (95% CI: 81.5\u201386.7%), which resulted in a false positive rate of 15.9%. The negative predictive value was 98.6% and the positive predictive value was 5.6%. Exploratory stage-adjusted sensitivity was 75.4% (95% CI:63.6\u201387.2%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The cfDNA assay demonstrated moderate specificity but limited sensitivity. Given the false positive rate of 15.9%, our results suggest that cfDNA-based assays for lung cancer may play a role as tools in combination with existing screening strategies pending continued validation. This proof-of-concept study is an important step in determining the feasibility of blood-based testing for early lung cancer detection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-15790-0","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T05:14:28Z","timestamp":1771996468000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Use of cell-free DNA in early detection of lung cancer: a proof-of concept study"],"prefix":"10.1186","volume":"26","author":[{"given":"Larissa L.","family":"White","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Maiyani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LeeAnn M.","family":"Quintana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Powers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay E.","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blythe","family":"Dollar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Bedoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"America Elias","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather Spencer","family":"Feigelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"15790_CR1","volume-title":"Cancer Facts & Figs. 2024","author":"American Cancer Society","year":"2024","unstructured":"American Cancer Society. Cancer Facts & Figs. 2024. Atlanta: American Cancer Society; 2024."},{"issue":"6","key":"15790_CR2","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.chest.2018.07.029","volume":"154","author":"A Thomas","year":"2018","unstructured":"Thomas A, Pattanayak P, Szabo E, Pinsky P. Characteristics and Outcomes of Small Cell Lung Cancer Detected by CT Screening. Chest. 2018;154(6):1284\u201390. https:\/\/doi.org\/10.1016\/j.chest.2018.07.029.","journal-title":"Chest"},{"issue":"5","key":"15790_CR3","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa1102873","volume":"365","author":"DR Aberle","year":"2011","unstructured":"National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395\u2013409. https:\/\/doi.org\/10.1056\/NEJMoa1102873.","journal-title":"N Engl J Med"},{"issue":"8","key":"15790_CR4","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1002\/cncr.35128","volume":"130","author":"TB Kratzer","year":"2024","unstructured":"Kratzer TB, Bandi P, Freedman ND, et al. Lung cancer statistics, 2023. Cancer. 2024;130(8):1330\u201348. https:\/\/doi.org\/10.1002\/cncr.35128.","journal-title":"Cancer"},{"issue":"10","key":"15790_CR5","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1001\/jama.2021.0377","volume":"325","author":"DE Jonas","year":"2021","unstructured":"Jonas DE, Reuland DS, Reddy SM, et al. Screening for Lung Cancer With Low-Dose Computed Tomography: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2021;325(10):971\u201387. https:\/\/doi.org\/10.1001\/jama.2021.0377.","journal-title":"JAMA"},{"issue":"1","key":"15790_CR6","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3322\/caac.21811","volume":"74","author":"AMD Wolf","year":"2024","unstructured":"Wolf AMD, Oeffinger KC, Shih TY, et al. Screening for lung cancer: 2023 guideline update from the American Cancer Society. CA Cancer J Clin. 2024;74(1):50\u201381. https:\/\/doi.org\/10.3322\/caac.21811.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"15790_CR7","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.chest.2023.02.003","volume":"164","author":"GA Silvestri","year":"2023","unstructured":"Silvestri GA, Goldman L, Tanner NT, et al. Outcomes From More Than 1 Million People Screened for Lung Cancer With Low-Dose CT Imaging. Chest. 2023;164(1):241\u201351. https:\/\/doi.org\/10.1016\/j.chest.2023.02.003.","journal-title":"Chest"},{"issue":"8","key":"15790_CR8","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1002\/cncr.33996","volume":"128","author":"L Sahar","year":"2022","unstructured":"Sahar L, Douangchai Wills VL, Liu KKA, et al. Geographic access to lung cancer screening among eligible adults living in rural and urban environments in the United States. Cancer. 2022;128(8):1584\u201394. https:\/\/doi.org\/10.1002\/cncr.33996.","journal-title":"Cancer"},{"issue":"5","key":"15790_CR9","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.chest.2018.10.039","volume":"155","author":"MS Kale","year":"2019","unstructured":"Kale MS, Wisnivesky J, Taioli E, Liu B. The Landscape of US Lung Cancer Screening Services. Chest. 2019;155(5):900\u20137. https:\/\/doi.org\/10.1016\/j.chest.2018.10.039.","journal-title":"Chest"},{"issue":"11","key":"15790_CR10","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1093\/jnci\/djac154","volume":"114","author":"AE Sedani","year":"2022","unstructured":"Sedani AE, Davis OC, Clifton SC, Campbell JE, Chou AF. Facilitators and Barriers to Implementation of Lung Cancer Screening: A Framework-Driven Systematic Review. J Natl Cancer Inst. 2022;114(11):1449\u201367. https:\/\/doi.org\/10.1093\/jnci\/djac154.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"15790_CR11","doi-asserted-by":"publisher","first-page":"e003127","DOI":"10.1136\/bmjresp-2024-003127","volume":"12","author":"M Salman","year":"2025","unstructured":"Salman M, Cotton A, Humphrey A, Domun T, Cheng C, Judah G. Patient barriers and facilitators to lung cancer screening uptake and intention to screen: a systematic review using the Theoretical Domains Framework. BMJ Open Respir Res. 2025;12(1):e003127. https:\/\/doi.org\/10.1136\/bmjresp-2024-003127.\u00a0","journal-title":"BMJ Open Respir Res"},{"issue":"4 Pt B","key":"15790_CR12","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.jacr.2018.12.028","volume":"16","author":"AK Borondy Kitts","year":"2019","unstructured":"Borondy Kitts AK. The Patient Perspective on Lung Cancer Screening and Health Disparities. J Am Coll Radiol. 2019;16(4 Pt B):601\u20136. https:\/\/doi.org\/10.1016\/j.jacr.2018.12.028.","journal-title":"J Am Coll Radiol"},{"issue":"7","key":"15790_CR13","doi-asserted-by":"publisher","first-page":"100331","DOI":"10.1016\/j.jtocrr.2022.100331","volume":"3","author":"KJ Kota","year":"2022","unstructured":"Kota KJ, Ji S, Bover-Manderski MT, Delnevo CD, Steinberg MB. Lung Cancer Screening Knowledge and Perceived Barriers Among Physicians in the United States. JTO Clin Res Rep. 2022;3(7):100331. https:\/\/doi.org\/10.1016\/j.jtocrr.2022.100331.\u00a0","journal-title":"JTO Clin Res Rep"},{"issue":"4","key":"15790_CR14","doi-asserted-by":"publisher","first-page":"339","DOI":"10.6004\/jnccn.2018.7101","volume":"17","author":"JA Lewis","year":"2019","unstructured":"Lewis JA, Chen H, Weaver KE, et al. Low Provider Knowledge Is Associated With Less Evidence-Based Lung Cancer Screening. J Natl Compr Canc Netw. 2019;17(4):339\u201346. https:\/\/doi.org\/10.6004\/jnccn.2018.7101.","journal-title":"J Natl Compr Canc Netw"},{"issue":"8","key":"15790_CR15","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1513\/AnnalsATS.201703-204PS","volume":"14","author":"L Carter-Harris","year":"2017","unstructured":"Carter-Harris L, Gould MK. Multilevel Barriers to the Successful Implementation of Lung Cancer Screening: Why Does It Have to Be So Hard? Ann Am Thorac Soc. 2017;14(8):1261\u20135. https:\/\/doi.org\/10.1513\/AnnalsATS.201703-204PS.","journal-title":"Ann Am Thorac Soc"},{"issue":"11","key":"15790_CR16","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1056\/NEJMoa2304714","volume":"390","author":"DC Chung","year":"2024","unstructured":"Chung DC, Gray DM 2nd, Singh H, et al. A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening. N Engl J Med. 2024;390(11):973\u201383. https:\/\/doi.org\/10.1056\/NEJMoa2304714.","journal-title":"N Engl J Med"},{"issue":"11","key":"15790_CR17","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1158\/2159-8290.CD-24-0519","volume":"14","author":"PJ Mazzone","year":"2024","unstructured":"Mazzone PJ, Bach PB, Carey J, et al. Clinical Validation of a Cell-Free DNA Fragmentome Assay for Augmentation of Lung Cancer Early Detection. Cancer Discov. 2024;14(11):2224\u201342. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-0519.","journal-title":"Cancer Discov"},{"key":"15790_CR18","unstructured":"American College of Radiology Committee on Lung-RADS\u00ae. Lung-RADS Assessment Categories. 2022. Available at https:\/\/www.acr.org\/-\/media\/ACR\/Files\/RADS\/Lung-RADS\/Lung-RADS-2022.pdf. Accessed on January 1, 2023."},{"issue":"1","key":"15790_CR19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1148\/radiol.2017161659","volume":"284","author":"H MacMahon","year":"2017","unstructured":"MacMahon H, Naidich DP, Goo JM, et al. Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017. Radiology. 2017;284(1):228\u201343. https:\/\/doi.org\/10.1148\/radiol.2017161659.","journal-title":"Radiology"},{"key":"15790_CR20","unstructured":"SEER*Explorer, National Cancer Institute. An interactive website for SEER cancer statistics. Surveillance Research Program. 2025. Available from: https:\/\/seer.cancer.gov\/statistics-network\/explorer\/. Data source(s): SEER Incidence Data, November 2024 Submission (1975\u20132022), SEER 21 registries.\u00a0[cited 2025 May 22]."},{"issue":"9","key":"15790_CR21","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/j.annonc.2020.05.028","volume":"31","author":"C Fiala","year":"2020","unstructured":"Fiala C, Diamandis EP. A multi-cancer detection test: focus on the positive predictive value. Ann Oncol. 2020;31(9):1267\u20138. https:\/\/doi.org\/10.1016\/j.annonc.2020.05.028.","journal-title":"Ann Oncol"},{"issue":"6","key":"15790_CR22","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1158\/1055-9965.EPI-24-1849","volume":"34","author":"Y Zhao","year":"2025","unstructured":"Zhao Y, Gulati R, Lange J, et al. Sensitivity Measures in Studies of Cancer Early Detection Biomarkers. Cancer Epidemiol Biomarkers Prev. 2025;34(6):944\u201351. https:\/\/doi.org\/10.1158\/1055-9965.EPI-24-1849.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"15790_CR23","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1177\/09691413231154801","volume":"30","author":"P Pinsky","year":"2023","unstructured":"Pinsky P, Lange J, Etzioni R. Estimating stage-specific sensitivity for cancer screening tests. J Med Screen. 2023;30(2):69\u201373. https:\/\/doi.org\/10.1177\/09691413231154801.","journal-title":"J Med Screen"},{"issue":"7802","key":"15790_CR24","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41586-020-2140-0","volume":"580","author":"JJ Chabon","year":"2020","unstructured":"Chabon JJ, Hamilton EG, Kurtz DM, et al. Integrating genomic features for non-invasive early lung cancer detection. Nature. 2020;580(7802):245\u201351. https:\/\/doi.org\/10.1038\/s41586-020-2140-0.","journal-title":"Nature"},{"issue":"1","key":"15790_CR25","doi-asserted-by":"publisher","first-page":"5060","DOI":"10.1038\/s41467-021-24994-w","volume":"12","author":"D Mathios","year":"2021","unstructured":"Mathios D, Johansen JS, Cristiano S, et al. Detection and characterization of lung cancer using cell-free DNA fragmentomes. Nat Commun. 2021;12(1):5060. https:\/\/doi.org\/10.1038\/s41467-021-24994-w.\u00a0","journal-title":"Nat Commun"},{"key":"15790_CR26","doi-asserted-by":"publisher","unstructured":"Cotner CE, O\u2019Donnell E. Understanding the Landscape of Multi-Cancer Detection Tests: The Current Data and Clinical Considerations. Life (Basel). 2024;14(7):896. https:\/\/doi.org\/10.3390\/life14070896.\u00a0","DOI":"10.3390\/life14070896"},{"key":"15790_CR27","doi-asserted-by":"publisher","unstructured":"Jonas DE, Reuland DS, Reddy SM, et al. Screening for Lung Cancer With Low-Dose Computed Tomography: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2021;325(10):971\u201387. https:\/\/doi.org\/10.1001\/jama.2021.0377.","DOI":"10.1001\/jama.2021.0377"},{"issue":"3","key":"15790_CR28","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1177\/0969141313500666","volume":"20","author":"PF Pinsky","year":"2013","unstructured":"Pinsky PF, Gierada DS, Nath H, Kazerooni EA, Amorosa J. ROC curves for low-dose CT in the National Lung Screening Trial. J Med Screen. 2013;20(3):165\u20138. https:\/\/doi.org\/10.1177\/0969141313500666. Medline:24009092.","journal-title":"J Med Screen"},{"issue":"22","key":"15790_CR29","doi-asserted-by":"publisher","first-page":"3976","DOI":"10.1002\/cncr.28326","volume":"119","author":"PF Pinsky","year":"2013","unstructured":"Pinsky PF, Church TR, Izmirlian G, Kramer BS. The National Lung Screening Trial: results stratified by demographics, smoking history, and lung cancer histology. Cancer. 2013;119(22):3976\u201383. https:\/\/doi.org\/10.1002\/cncr.28326. Medline:24037918.","journal-title":"Cancer"},{"key":"15790_CR30","doi-asserted-by":"publisher","first-page":"5","DOI":"10.21037\/ccts-20-171","volume":"5","author":"HN Marmor","year":"2023","unstructured":"Marmor HN, Zorn JT, Deppen SA, Massion PP, Grogan EL. Biomarkers in Lung Cancer Screening: a Narrative Review. Curr Chall Thorac Surg. 2023;5:5. https:\/\/doi.org\/10.21037\/ccts-20-171.","journal-title":"Curr Chall Thorac Surg"},{"issue":"4","key":"15790_CR31","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.chest.2023.05.025","volume":"164","author":"R Paez","year":"2023","unstructured":"Paez R, Kammer MN, Tanner NT, et al. Update on Biomarkers for the Stratification of Indeterminate Pulmonary Nodules. Chest. 2023;164(4):1028\u201341. https:\/\/doi.org\/10.1016\/j.chest.2023.05.025.","journal-title":"Chest"},{"issue":"1","key":"15790_CR32","doi-asserted-by":"publisher","first-page":"100130","DOI":"10.1016\/j.chpulm.2024.100130","volume":"3","author":"KJ Long","year":"2025","unstructured":"Long KJ, Silvestri GA, Kammer MN, et al. Validation of a High-Specificity Blood Autoantibody Test to Detect Lung Cancer in Pulmonary Nodules. CHEST Pulm. 2025;3(1):100130. https:\/\/doi.org\/10.1016\/j.chpulm.2024.100130.","journal-title":"CHEST Pulm"},{"key":"15790_CR33","doi-asserted-by":"publisher","unstructured":"Driussi A, Lamaze FC, Kordahi M, et al. Clinicopathological Predictors of the Presence of Blood Circulating Tumor DNA in Early-Stage Non-Small Cell Lung Cancers. Mod Pathol. 2025;26. https:\/\/doi.org\/10.1016\/j.modpat.2025.100744.","DOI":"10.1016\/j.modpat.2025.100744"},{"issue":"16","key":"15790_CR34","doi-asserted-by":"publisher","first-page":"4911","DOI":"10.3390\/jcm13164911","volume":"13","author":"LB Cotton","year":"2024","unstructured":"Cotton LB, Bach PB, Cisar C, et al. Innovations in Early Lung Cancer Detection: Tracing the Evolution and Advancements in Screening. J Clin Med. 2024;13(16):4911. https:\/\/doi.org\/10.3390\/jcm13164911.\u00a0","journal-title":"J Clin Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15790-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15790-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15790-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:50:06Z","timestamp":1781635806000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15790-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15790"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15790-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"assertion":[{"value":"28 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all participants in this study. The study was approved by the Kaiser Permanente Interregional Institutional Review Board (#1516657-23). All methods were carried out in accordance with relevant guidelines and regulations (declaration of Helsinki).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"432"}}